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Background: People who inject drugs (PWID) are disproportionately affected by both HIV and hepatitis C infection
(HCV). Awareness of infection status is essential to ensure linkage to appropriate healthcare for those infected, who
need treatment and regular follow-up, as well as for uninfected individuals, who need access to targeted testing
and counselling services. In this paper we compare self-reported HIV and HCV status with serological markers of
infection among PWID recruited through respondent driven sampling.
Methods: From 2011 through 2014, biological and behavioural data was collected from 2,077 PWID in Germany.
Dried blood spots from capillary blood samples were collected and screened for HCV antibodies, HCV RNA and
HIV-1/-2 antibodies. HIV reactive samples were confirmed by Western blot.
Results: Laboratory testing revealed that 5 % were infected with HIV and 81 % were aware of being infected.
Chronic HCV infection was detected in 41 % of the participants, 2 % had an acute HCV infection, 22 % had a
cleared infection, and 34 % were unexposed to HCV. The concordance between self-reported and measured HCV
status was lower than for HIV, with 73 % of those with chronic HCV infection being aware of their infection.
Conclusions: We found a relatively high awareness of HIV and HCV infection status among PWID. Nevertheless,
access to appropriate testing, counselling and care services targeted to the needs of PWID should be further
improved, particularly concerning HCV.
Trial registration: Ethical approval was received from the ethics committee at the medical university of Charité,
Berlin, Germany in May 2011 and with an amendment approved retrospectively on 19/11/2012 (No EA4/036/11).
The German Federal Commissioner for Data Protection and Freedom of Information approved the study protocol
retrospectively on 29/11/2012 (III-401/008#0035).
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Accurate knowledge of infection status is important as it
gives infected individuals the opportunity to seek appro-
priate healthcare and may encourage people to engage
in preventive behaviours, which can protect themselves
and others from infections. People who inject drugs
(PWID) have a high risk and burden of both HIV and
Hepatitis C infection (HCV) [1–4]. Determining HIV in-
fection status is relatively straightforward since there is
no clearance or cure. In contrast, screening for HCV
antibodies (anti-HCV) will identify if a person has ever
been in contact with the virus, but this person may have
cleared the infection either with treatment or spontan-
eously, or the person may have a chronic HCV infection,
characterised by being both anti-HCV and HCV RNA
positive. A person who has cleared the infection can
later be re-infected with HCV. Since the acquisition of
both HIV and HCV is often asymptomatic or the occur-
rence of non-specific symptoms may be attributed to
other problems, and since serious sequelae may take sev-
eral decades to develop, people infected with these two
viruses may remain unaware of being infected for a long
period of time. Annual routine unlinked anonymous
monitoring (UAM) of HIV and hepatitis among PWID
in England, Wales and Northern Ireland has shown that
the proportion of infected PWID unaware of their infec-
tion varied between 4 %-15 % for HIV and 45 %-53 %
for HCV in the period 2010–2014 [5]. In a recent sys-
tematic review including 11 studies from five EU coun-
tries the proportion of undiagnosed HCV infections
among PWID varied between 24 %-76 % (IQR: 38 %-64 %
and median: 49 %) [4]. Several previous studies only
looked at anti-HCV status and did not include HCV
RNA status, which is needed to assess current infection
status [4–6].
With new, highly effective and well tolerable HCV
therapy options being available as well as the potential
of HIV-treatment as prevention also among PWID [7], it
is of growing importance to increase awareness of infec-
tion status.
In order to assess the level of awareness of infection
status among PWID in Germany, we used data from a
recent, cross-sectional bio-behavioural survey of this
population to compare self-reported HIV and HCV sta-
tus with serological markers of infection.
Methods
The DRUCK-study collected biological and behavioural
data from 2,077 PWID in eight large German cities in
the years 2011–2014 [8]. The respondents were re-
cruited using respondent driven sampling. Inclusion cri-
teria were a minimum age of 16 years, having injected
drugs in the given study city in the last 12 months, and
providing informed consent for study participation. Allparticipants went through a questionnaire-assisted inter-
view and provided a capillary blood sample, collected as
dried blood spots (DBS). Samples and questionnaires
were marked with the same unique identifier. The study
was piloted in two cities and then implemented in the
remaining six. Before starting the data collection we
trained interviewers to increase their understanding of
HIV and HCV, and laboratory staff for collection of DBS
and handling and shipping of the samples in each of the
study cities to ensure the comparability of results. All
samples were screened for anti-HIV-1/-2 by EIA, and re-
active samples were confirmed by Western blot. In six of
the eight study cities, all samples were screened for both
anti-HCV by EIA and analysed for the presence of
HCV-RNA using nested RT-PCR. Anti-HCV positive
samples were confirmed by immunoblot. In the two
pilot cities all samples were screened for anti-HCV by
EIA and RT-PCR was performed on all anti-HCV posi-
tive samples and on anti-HCV negative samples if test
results did not correspond to self-reported results. The
test specificity was 100 % for all three markers: anti-HIV,
anti-HCV and HCV RNA. The same was true for the
sensitivity for HIV and HCV RNA, whereas the sensitiv-
ity for anti-HCV was 97.8 % [9]. Further information
about study design, data collection and laboratory
methods etc. has been published elsewhere [8, 9].
Defining self-reported HIV status
The self-reported HIV status was determined using two
questions: if the participant had ever been tested for
HIV and if yes, what the result of their latest test was.
Based on the answers participants were categorised as
HIV negative, HIV positive or never tested. Participant’s
self-reported HIV status were categorised as unclear
when they were not sure if they had ever been tested or
if they did not know their last test result. Participants
who reported having been diagnosed with HIV were
asked about month and year of their first positive HIV
test in order to calculate how long they had been aware
of being infected.
Defining measured HIV status
We defined samples as HIV positive if testing positive
for anti-HIV with EIA and being confirmed by Western
blot. EIA-reactive samples with indeterminate immuno-
blot pattern were excluded from this analysis. Anti-HIV
negative samples were determined as HIV negative.
Defining self-reported HCV status
To determine the self-reported HCV status several ques-
tions were used. Participants were asked if they had ever
been tested for anti-HCV. Those who had not were cate-
gorised as never tested. The participants who reported
testing for HCV were further asked if they had ever
Table 1 Concordance of self-reported and measured HIV status,
n=2076 (excluding one sample with indeterminate HIV status)
HIV laboratory test results
Self-reported status HIV negative (AB-) HIV positive (AB+)
Concordant 1784 (90 %) 81 (81 %)
Discordant 6 (0,3 %) 16 (16 %)
Never tested 133 (7 %) 1 (1 %)
Unclear 52 (3 %) 0 (0 %)
Answer declined 1 (0,1 %) 2 (2 %)
Total 1976 100
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not were categorised as uninfected. Participants report-
ing having ever received a positive anti-HCV test result
were further asked if they had ever been successfully
treated or had cleared the infection spontaneously.
Those who responded no to both questions were cate-
gorised as infected, while those who responded yes to ei-
ther of the questions were defined as previously infected.
As for HIV, participants who were either not sure if they
had ever been tested or did not know their last test re-
sult, were categorised as unclear.Unclear means not sure if tested or did not get last test result.
AB antibodiesDefining measured HCV status
We defined chronic HCV infection as testing anti-HCV
and RNA positive, acute infection (HCV infection ac-
quired within the last 4–6 weeks) as anti-HCV negative,
but RNA positive, cleared infection as anti-HCV positive
and HCV RNA negative, and unexposed as testing anti-
HCV and RNA negative.
An example of the questionnaire used to guide the in-
terviews can be found online [10].Results
In total, 2,077 PWID from eight German cities were in-
cluded in the study, with the proportion of female par-
ticipants ranging between 19 %-35 % in the respective
cities, and a median age ranging between 29–41 years.HIV status
The laboratory testing revealed 100 participants (4.8 %)
to be positive for HIV, and 1976 (95.2 %) to be negative.
One sample had a reactive EIA result but an indetermin-
ate immunoblot, and was thus excluded from the ana-
lysis. Of the 100 HIV positive cases, 81 % were aware of
their infection while 16 % reported their last HIV test to
be negative. One HIV positive participant reported no
previous testing.
Among the participants testing negative for HIV, 90 %
reported a negative test result at last test, while 7 % re-
ported never having had an HIV test. Of the HIV nega-
tive participants, six individuals (0.3 %) reported having
received a positive HIV-test result. Two HIV positive
and one HIV negative participant declined to answer the
question on HIV-status. The concordance of the self-
reported HIV status and laboratory test results is dis-
played in Table 1.
Among the 81 self-reported HIV infected, 5 % re-
ported receiving their diagnosis in the last year, 17 %
1–5 years ago, 22 % 6–10 years ago and 47 % more
than 10 years ago. Seven cases (9 %) did not provide in-
formation on time of their HIV diagnosis.HCV status
The laboratory tests found 716 (34 %) participants to be
unexposed to HCV, 857 (41 %) participants to have a
chronic HCV infection and 457 (22 %) participants with a
cleared HCV infection. In 47 (2 %) participants HCV-RNA
but no anti-HCV was detected, indicating an acute infec-
tion. As the participants were only asked about anti-HCV
test results, this group was excluded from the analysis.
The concordance between the self-reported HCV sta-
tus and the laboratory test results was 47 % among those
unexposed, while 27 % reported an HCV status discord-
ant to the laboratory findings (Table 2). Of these, 56 %
reported a current HCV infection and 44 % a previous
one (Table 3). Of all unexposed individuals, 16 % re-
ported never to have had a test for HCV. In the group
with confirmed, chronic HCV infections, 73 % reported
a status concordant to the laboratory test results,
whereas 19 % reported a differing HCV status. In 37 %
of these discordant cases, participants reported to be un-
infected and in 63 % a cleared infection. Among partici-
pants positive only for anti-HCV but not HCV-RNA,
i.e., with a cleared infection, 38 % correctly reported to
have cleared the infection. Of those reporting a dis-
cordant status, 89 % reported to be currently infected
and 11 % reported an uninfected status.
Discussion
In our study population of PWID, the concordance of
self-reported and measured HIV status was relatively
high. The proportion of HIV positive participants aware
of their infection was 81 %. These data compare well
with the data from both the UAM in England, Wales
and northern Ireland from 2010–2014 where 85-96 % of
HIV positive PWID were aware of their HIV infection
[5] and the latest HIV modelling data from Germany,
where it was estimated that 89 % (81-93 %) of all HIV
infected PWID living in Germany in 2014 had received
an HIV diagnosis [11]. According to the same HIV mod-
elling data for Germany, the proportion of HIV infected
individuals who are aware of their HIV status is higher
Table 2 Concordance of self-reported and measured HCV status, n=2030 (excluding cases with acute infection)
HCV laboratory test results
Self-reported status Unexposed (AB-, RNA-) Chronic infection (AB+, RNA+) Cleared infection (AB+, RNA-)
Concordant 339 (47 %) 622 (73 %) 174 (38 %)
Discordant 194 (27 %) 163 (19 %) 254 (56 %)
Never tested 113 (16 %) 37 (4 %) 15 (3 %)
Unclear 69 (10 %) 35 (4 %) 14 (3 %)
Answer declined 1 (0,1 %) 0 (0 %) 0 (0 %)
Total 716 857 457
Unclear means not sure if tested or did not get last test result
AB antibodies
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who have sex with men (MSM) (82 % (79-85 %)) and non-
injecting heterosexuals (74 % (66-80 %)). This might partly
be explained by the fact that the majority of HIV infec-
tions among PWID in Germany were acquired in the
1980ies and 90ies, which is also seen by the high propor-
tion of known HIV infections being diagnosed more than
10 years ago. This means that the majority of HIV infected
PWID have had many years to get a diagnosis and begin
therapy. Increasing treatment rates among PWID may
have a relatively large impact on reducing potential
sources of HIV transmission within this population [7]. A
low rate of newly acquired HIV infections is also indicated
by the fact that <1 % of PWID not yet tested for HIV were
found to be anti-HIV positive in our study. The one
sample with a reactive AB test and indeterminate immu-
noblot could be a recent infection in the stage of serocon-
version. We tried to receive a second blood sample from
this participant to repeat the testing, but the person did
not show up in the drug service again.
The finding that 17 % of those positive for HIV re-
ported a negative HIV status or to never have been
tested, underlines the undiminished importance of en-
suring access to targeted HIV testing and counselling
services for PWID in Germany, e.g., in low threshold
settings.
For the disconcerting finding of six self-reported infec-
tions in participants without measurable anti-HIV several
possible explanations exist. One possibility is the failure to
detect antibodies in excessively diluted samples if the ori-
ginal amount of capillary blood was inadequately small,Table 3 Discordance of self-reported and measured HCV status, n=6
HCV laboratory test results
Self-reported status Unexposed (AB-, RNA-)
Uninfected
Infected 109 (56 %)
Previously infected (cleared infection) 85 (44 %)
Total 194
AB antibodiesresulting in a higher dilution of the antibodies as com-
pared to the standardized and validated protocol. Further
we cannot rule out the communication of false positive
test results to study participants, in particular if reactive
screening test results were not confirmed, which can hap-
pen if respondents were not linked into care. Processing
mistakes during sample collection or during testing of
DBS, or the disappearance of HIV antibodies if treatment
has been started early and viral load has remained sup-
pressed continuously are further, though in our view less
likely possibilities.
The results of the HCV testing revealed that 34 %
were unexposed to HCV, 2 % had an acute HCV infec-
tion, 41 % of participants had a chronic infection and 22
% had a cleared infection. It is possible that a few acute
HCV infections might have been missed in the two first
pilot cities where PCR was only done for anti-HCV
negative respondents with a self-reported HCV diagno-
sis. The concordance between self-reported and actual
HCV status was much lower than for HIV. Concordance
was highest (73 %) among those with a chronic in-
fection, 47 % among those unexposed to HCV and just
38 % among those with a cleared infection.
The somewhat surprising finding of 27 % of those with
no markers of HCV infection reporting to be infected
(chronic or cleared HCV), might partly be explained by
confusion about the different types of hepatitis, e.g., par-
ticipants may previously have received a positive test re-
sult for hepatitis B. Another explanation could be the
failure to detect antibodies e.g., due to excessive dilution,
as described above for HIV or a false negative anti-HCV11
Chronic infection (AB+, RNA+) Cleared infection (AB+, RNA-)
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sitivity of 97.8 %.
Of the participants with a chronic HCV infection, 27 %
falsely believed to be uninfected, to have cleared the infec-
tion or had never been tested or were not sure of their test
result. This rate is much lower than what is reported from
the UAM in England, Wales and northern Ireland where
45-53 % of anti-HCV positive were unaware of their HCV
infection in the years 2010–2014 [5]. Also the recent sys-
tematic review on HCV in PWID in Europe found higher
rates of undiagnosed HCV: 24-76 % (IQR: 38-64 % and
median: 49 %) [4]. An Australian study of 352 active injec-
tors under the age of 30, found rates of concordance simi-
lar to our study: 68 % among those with a chronic
infection and 46 % among those with a cleared HCV in-
fection [12]. Also data from a French study of HCV
among PWID found that only 22 % of PWID were un-
aware of their HCV infection [13, 14]. A recently pub-
lished study from Spain presents data on the proportion
of undiagnosed HCV infection among PWID stratified by
migration status and duration of injecting. This study re-
ports rates of undiagnosed HCV from 15 % among
Spanish long-term injectors up to 57 % among migrant
new injectors [6]. All these data suggest that awareness of
HCV infection status among PWID in Germany is rela-
tively high. This is also true when comparing with data for
the general population in Europe, where between 40 %
and 80 % of people with chronic hepatitis are believed to
be unaware of their infection [15]. However, the persons
indicating a true positive anti-HCV test result often do
not necessarily also know their PCR test result. In times of
effective treatment options for HCV this will become in-
creasingly important.
In our study, the majority (63 %) of those with a
chronic HCV infection with a discordant self-reported
status were aware of having been exposed to the virus
but believed to have cleared the infection. These partici-
pants might have simply assumed to be healed (we did
not collect data on whether the reported clearance had
been laboratory confirmed) or they might indeed have
cleared the virus but later become re-infected. These re-
sults show the need of special screening efforts of PWID
who have once cleared their HCV infection, as re-
infections can only be diagnosed by detecting the viral
RNA.
From a public health point of view, the most undesir-
able discordant status is being infected and either not
being aware of being infected or believing to be unin-
fected. This discrepancy between perception and reality
limits the access to appropriate health care and may in-
crease the risk of unknowingly transmitting infections.
However, the evidence about the association between
knowledge of HCV status and risk behaviours in PWID
is conflicting. Some longitudinal studies have observed areduction in risky injecting drug use following notifica-
tion of HCV-positive status [16, 17], while other studies
found either no reduction or even increased risky injec-
tion behaviours among PWID receiving a diagnosis of
HCV infection [18, 19]. This means that believing to be
infected, while actually being uninfected may turn out to
become a self-fulfilling prophecy. As mentioned in the
results, it was common among both unexposed partici-
pants, as well as participants with a cleared infection, to
wrongly believe they were currently infected. It might be
that those who have been at risk assume they are in-
fected and/or do not believe their test results.
Studying HCV infection status and HCV test status is
complicated and not only our study participants, but in our
experience also both non-medical and medical staff often
had difficulties in distinguishing between the two HCV
tests (AB and RNA) and in interpreting the combination of
the two test results. Our findings, as are those from other,
similar studies, are limited by the lack of clarity regarding
HCV test and infection status among both interviewers and
respondents. Several qualitative studies among PWID have
shown that confusion and uncertainty regarding the mean-
ing of a positive HCV test and HCV risk exist in this group
and that HCV is often perceived as an almost inevitable
consequence of drug injecting [20–22].
Our data is collected from eight large cities in
Germany, but is not likely to be representative for all
PWID living in Germany. E.g. our study sample might
be more knowledgeable about their infection status than
PWID living in smaller cities due to better access to
drug user services, testing and treatment in larger cities.
Conclusion
In our study, 17 % of HIV positive PWID and 27 % of those
with chronic HCV infection were unaware of their infec-
tions. These results indicate that the majority of the study
population is aware of their infection status, however still
more than a quarter of those with infectious HCV and
nearly one in five of HIV infected PWID in our study sam-
ple did not know their status, although they were often at-
tached to opioid substitution therapy or other harm
reduction services. Not being aware of the infection status
implies that they cannot access appropriate health care and
they risk unknowingly transmitting the disease to others.
In line with several other studies, we also believe that
the quality of post-test counselling is crucial for increas-
ing awareness of infection status as well as for ensuring
a positive impact on risk behaviours and ensuring link-
age to care and appropriate medical services for both in-
fected and uninfected PWID. In the era of highly
effective antiviral HCV-treatment options, the opportun-
ity is there to clear infection in almost all HCV-infected
PWID, if infected persons become aware of their status
and are linked to care.
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